Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced that Thomas H. Silberg, who had previously served as the company’s executive vice president, commercial operations & operational excellence, has now been named as president of Abraxis Pharmaceutical Products (APP), and Frank Harmon, who has served as executive vice president, global operations, will now report to Silberg and assume the role of chief operating officer for the APP division. It was also announced that Richard E. Maroun, the company’s chief administrative officer, will add to his current responsibilities and assume the role of general counsel and corporate secretary. Maroun, Silberg and Harmon will continue to serve on the Executive Committee for Abraxis BioScience.
